From the Journals

Study finds COVID-19 boosters don’t increase miscarriage risk


 

FROM JAMA NETWORK OPEN

COVID-19 boosters are not linked to an increased chance of miscarriage, according to a new study in JAMA Network Open.

Researchers were seeking to learn whether a booster in early pregnancy, before 20 weeks, was associated with greater likelihood of spontaneous abortion.

They examined more than 100,000 pregnancies at 6-19 weeks from eight health systems in the Vaccine Safety Datalink (VSD). They found that receiving a COVID-19 booster shot in a 28-day or 42-day exposure window did not increase the chances of miscarriage.

“These findings support the safety of COVID-19 booster vaccination in early pregnancy,” they wrote.

The VSD is a collaboration between the Centers for Disease Control and Prevention’s Immunization Safety Office and large health care systems. The “observational, case-control, surveillance study” was conducted from Nov. 1, 2021, to June 12, 2022.

“COVID infection during pregnancy increases risk of poor outcomes, yet many people who are pregnant or thinking about getting pregnant are hesitant to get a booster dose because of questions about safety,” said Elyse Kharbanda, MD, senior investigator at HealthPartners Institute and lead author of the study in a press release.

The University of Minnesota reported that “previous studies have shown COIVD-19 primary vaccination is safe in pregnancy and not associated with an increased risk for miscarriage. Several studies have also shown COVID-19 can be more severe in pregnancy and lead to worse outcomes for the mother.”

The study was funded by the CDC. Five study authors reported conflicts of interest with Pfizer, Merck, GlaxoSmithKline, AbbVie, and Sanofi Pasteur.

A version of this article first appeared on Medscape.com.

Recommended Reading

Explanation proposed for long-COVID symptoms in the CNS
Journal of Clinical Outcomes Management
Diagnosis by dog: Canines detect COVID in schoolchildren with no symptoms
Journal of Clinical Outcomes Management
Long-COVID patients respond differently to COVID vaccines
Journal of Clinical Outcomes Management
Researchers seek to understand post-COVID autoimmune disease risk
Journal of Clinical Outcomes Management
New drugs in primary care: Lessons learned from COVID-19
Journal of Clinical Outcomes Management
Study of hospitalizations in Canada quantifies benefit of COVID-19 vaccine to reduce death, ICU admissions
Journal of Clinical Outcomes Management
Clinical trials: Top priority for long COVID
Journal of Clinical Outcomes Management
CDC cuts back hospital data reporting on COVID
Journal of Clinical Outcomes Management
Review supports continued mask-wearing in health care visits
Journal of Clinical Outcomes Management
COVID boosters effective, but not for long
Journal of Clinical Outcomes Management